221 related articles for article (PubMed ID: 29906493)
21. Effect of acute and subchronic administration of (R)-WIN55,212-2 induced neuroprotection and anti inflammatory actions in rat retina: CB1 and CB2 receptor involvement.
Spyridakos D; Papadogkonaki S; Dionysopoulou S; Mastrodimou N; Polioudaki H; Thermos K
Neurochem Int; 2021 Jan; 142():104907. PubMed ID: 33220388
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
[TBL] [Abstract][Full Text] [Related]
23. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
24. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
25. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.
Ikeda H; Ikegami M; Kai M; Ohsawa M; Kamei J
Neuroscience; 2013 Oct; 250():446-54. PubMed ID: 23892011
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Tintori C; Tuccinardi T; Vincenzi F; Borea PA; Varani K
J Med Chem; 2013 Jun; 56(11):4482-96. PubMed ID: 23697626
[TBL] [Abstract][Full Text] [Related]
27. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
29. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
Bolognini D; Cascio MG; Parolaro D; Pertwee RG
Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724
[TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.
Feng YJ; Li YY; Lin XH; Li K; Cao MH
World J Gastroenterol; 2016 Nov; 22(43):9515-9524. PubMed ID: 27920472
[TBL] [Abstract][Full Text] [Related]
31. CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes.
Nieri P; Greco R; Adinolfi B; Breschi MC; Martinotti E; Nannetti C; Podestà A
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):352-9. PubMed ID: 14566452
[TBL] [Abstract][Full Text] [Related]
32. The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft.
Scuderi MR; Cantarella G; Scollo M; Lempereur L; Palumbo M; Saccani-Jotti G; Bernardini R
Cancer Lett; 2011 Nov; 310(2):240-9. PubMed ID: 21807457
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
34. Identification of raloxifene as a novel CB2 inverse agonist.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2013 May; 435(1):76-81. PubMed ID: 23611779
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
37. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
Slipetz DM; O'Neill GP; Favreau L; Dufresne C; Gallant M; Gareau Y; Guay D; Labelle M; Metters KM
Mol Pharmacol; 1995 Aug; 48(2):352-61. PubMed ID: 7651369
[TBL] [Abstract][Full Text] [Related]
38. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
Yang P; Wang L; Feng R; Almehizia AA; Tong Q; Myint KZ; Ouyang Q; Alqarni MH; Wang L; Xie XQ
J Med Chem; 2013 Mar; 56(5):2045-58. PubMed ID: 23406429
[TBL] [Abstract][Full Text] [Related]
39. Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.
Rizzo V; Carletti F; Gambino G; Schiera G; Cannizzaro C; Ferraro G; Sardo P
Epilepsy Res; 2014 Dec; 108(10):1711-8. PubMed ID: 25458534
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
Sarfaraz S; Afaq F; Adhami VM; Mukhtar H
Cancer Res; 2005 Mar; 65(5):1635-41. PubMed ID: 15753356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
